Business Context and Reporting Period
Company: Natural Alternatives International, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2002 (First Quarter of Fiscal 2003)
Business Overview: The Company manufactures and distributes dietary supplements, vitamins, and minerals. Operations include contract manufacturing and direct-to-consumer sales, with significant international presence through a subsidiary in Switzerland (NAIE).
Key Financial Metrics
| Metric (in thousands) | Q1 2003 (Sep 30, 2002) | Q1 2002 (Sep 30, 2001) |
|---|---|---|
| Net Sales | $13,136 | $9,887 |
| Gross Profit | $3,195 | $2,024 |
| Gross Margin | 24.3% | 20.5% |
| Operating Income | $403 | ($430) |
| Net Income | $537 | ($658) |
| Diluted EPS | $0.09 | ($0.11) |
| Cash from Operations | $1,109 | ($474) |
| Cash & Equivalents (End of Period) | $2,824 | $792 |
| Total Debt (Current + Long-term) | $3,408 | N/A |
Note: Debt figures derived from Balance Sheet line items (Line of credit, Current portion of long-term debt, Long-term debt). Total debt at Sep 30, 2002 was $3.4 million ($1.386M line of credit + $0.601M current debt + $1.421M long-term debt).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 32% to $13.1 million, driven by a 34% increase in contract manufacturing sales ($10.5M) and a 29% increase in direct-to-consumer sales ($2.6M).
- Profitability Turnaround: The Company returned to profitability with $537,000 in net income, reversing a $658,000 loss in the prior year. Operating income improved by $833,000.
- Margin Expansion: Gross margin improved to 24.3% from 20.5%, attributed to fixed cost leverage from higher volumes, despite material costs rising to 52% of sales.
- Unusual Items: Net income included a one-time $225,000 gain from the final settlement of the Vitamin Antitrust Litigation.
- Liquidity: Cash and cash equivalents increased significantly from $640,000 to $2.8 million, aided by $1.1 million in operating cash flow and new financing.
Guidance, Outlook, and Risks
Management Commentary & Outlook
Management expects operating results to fluctuate due to timing of revenue recognition and expenses. The Company believes current cash and credit facilities are sufficient for near-term operations. Growth strategies include expanding European operations and diversifying the customer base.
Material Risks & Contingencies
- Customer Concentration: Two customers accounted for 64% of net sales in Q1 2003. Loss of either would have a material adverse impact.
- Supplier Concentration: Three suppliers accounted for 47% of raw material purchases. The Company relies on a single supplier to process materials for its largest customer.
- Key Personality Risk: Direct-to-consumer sales (approx. 20% of total) rely heavily on a key personality for marketing; loss of this individual or media exposure poses a risk.
- Regulatory Environment: Operations are subject to FDA and FTC regulations regarding dietary supplements. Future regulations could require product reformulation or recalls.
- Financing: A new $6.5 million credit facility (effective Oct 31, 2002) replaced expiring lines of credit. Failure to maintain this facility could impair growth funding.
Investor Verification Checklist
- Customer Dependency: Verify the stability of contracts with the two major customers representing 64% of revenue.
- Antitrust Proceeds: Confirm the $225,000 litigation settlement was a one-time event and not indicative of recurring non-operating income.
- Debt Covenants: Review the terms of the new $6.5 million credit facility entered into October 31, 2002, specifically regarding eligibility requirements for receivables and inventory.
- Inventory Valuation: Assess the adequacy of inventory reserves given the increase in raw material costs and the risk of obsolescence.
- International Exposure: Evaluate risks associated with the Swiss subsidiary (NAIE), including currency fluctuations and regulatory barriers in international markets.